<p>ImmuCell Corporation（納斯達克代碼：ICCC - 獲取免費報告）在週二的交易中跌破了其 200 日移動平均線。該股票的 200 日移動平均線為 6.15 美元，最低交易價為 5.80 美元。ImmuCell 的股票最後交易價為 5.82 美元，成交量為 45,363 股。</p>
<h2>華爾街分析師觀點</h2>
<p>另外，Weiss Ratings 在週一的報告中重申了對 ImmuCell 股票的 “賣出（d+）” 評級。一位股票研究分析師對該股票給予了賣出評級，根據 MarketBeat 的數據，ImmuCell 目前的平均評級為 “賣出”。</p>
<p><strong>查看我們關於 ICCC 的最新研究報告</strong></p>
<h2>ImmuCell 價格表現</h2>
<p>該股票的 50 日移動平均線為 5.72 美元，200 日移動平均線為 6.15 美元。該公司的市值為 5267 萬美元，市盈率為 22.39，貝塔值為 0.20。公司當前比率為 4.21，速動比率為 1.76，債務股本比率為 0.27。</p>
<p>ImmuCell（納斯達克代碼：ICCC - 獲取免費報告）最近在 11 月 13 日（星期四）發佈了季度財報。這家生物技術公司報告的每股收益（EPS）為（0.02）美元。ImmuCell 的股本回報率為 8.00%，淨利潤率為 8.37%。該公司在本季度的收入為 555 萬美元。</p>
<h2>對 ImmuCell 的對沖基金觀點</h2>
<p>一家對沖基金最近增加了對 ImmuCell 股票的持股。根據該公司在最近向證券交易委員會提交的 13F 文件，Geode Capital Management LLC 在第二季度將其在 ImmuCell Corporation（納斯達克代碼：ICCC - 免費報告）的持股增加了 4.2%。該公司在本季度購買了額外的 2,907 股後，持有 71,852 股生物技術公司的股票。Geode Capital Management LLC 在最近一個季度末持有 ImmuCell 的 0.79%，價值 50 萬美元。13.47% 的股票由機構投資者持有。</p>
<h2>關於 ImmuCell</h2>
<p>（獲取免費報告）</p>
<p>ImmuCell Corporation（納斯達克代碼：ICCC）是一家生物技術公司，開發、製造和銷售旨在增強奶牛和肉牛健康的免疫產品和診斷試劑。公司總部位於緬因州波特蘭，專注於通過其被動免疫解決方案和獸醫診斷產品支持羣體健康管理。</p>
<p>該公司的旗艦產品 CalfGuard 天然初乳補充劑旨在促進新生小牛抗體的被動轉移，並減少新生疾病的發生率。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票比 ImmuCell 更好</li>
<li>可能每月支付高達 4,290 美元的無聊 AI 投資</li>
<li>特朗普的 “美國房地產交易” 解析</li>
<li>在 1 月 1 日之前投資 1,000 美元於這隻股票 [不是 NVDA]</li>
<li>警報：在 2026 年 1 月之前拋售這五隻股票！</li>
<li>特朗普做了什麼？？</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元於 ImmuCell 嗎？</h2>
<p>在考慮 ImmuCell 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 ImmuCell 並不在名單上。</p>
<p>雖然 ImmuCell 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

ICCC

<p>ImmuCell Corporation 的股票（NASDAQ: ICCC）已跌破其 200 日移動平均線，最低交易價格為 5.80 美元。分析師對該股票給予了 “賣出” 評級，目前市值為 5267 萬美元。該公司報告的季度收入為 551 萬美元，淨利潤率為 8.37%。Geode Capital Management 在第二季度增持了 ImmuCell 4.2% 的股份。ImmuCell 專注於動物健康的免疫產品，特別是在奶牛和肉牛領域</p>

<p>ImmuCell Corporation (NASDAQ:ICCC - Get Free Report) crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $6.15 and traded as low as $5.80. ImmuCell shares last traded at $5.82, with a volume of 45,363 shares changing hands.</p>
<div class="lb-trans"><p>ImmuCell Corporation（納斯達克代碼：ICCC - 獲取免費報告）在週二的交易中跌破了其 200 日移動平均線。該股票的 200 日移動平均線為 6.15 美元，最低交易價為 5.80 美元。ImmuCell 的股票最後交易價為 5.82 美元，成交量為 45,363 股。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Separately, Weiss Ratings reiterated a &#34;sell (d+)&#34; rating on shares of ImmuCell in a report on Monday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, ImmuCell presently has an average rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在週一的報告中重申了對 ImmuCell 股票的 “賣出（d+）” 評級。一位股票研究分析師對該股票給予了賣出評級，根據 MarketBeat 的數據，ImmuCell 目前的平均評級為 “賣出”。</p>
</div><p><strong>Check Out Our Latest Research Report on ICCC</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 ICCC 的最新研究報告</strong></p>
</div><h2>ImmuCell Price Performance</h2>
<div class="lb-trans"><h2>ImmuCell 價格表現</h2>
</div><p>The stock has a 50-day moving average of $5.72 and a two-hundred day moving average of $6.15. The firm has a market cap of $52.67 million, a price-to-earnings ratio of 22.39 and a beta of 0.20. The company has a current ratio of 4.21, a quick ratio of 1.76 and a debt-to-equity ratio of 0.27.</p>
<div class="lb-trans"><p>該股票的 50 日移動平均線為 5.72 美元，200 日移動平均線為 6.15 美元。該公司的市值為 5267 萬美元，市盈率為 22.39，貝塔值為 0.20。公司當前比率為 4.21，速動比率為 1.76，債務股本比率為 0.27。</p>
</div><p>ImmuCell (NASDAQ:ICCC - Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. ImmuCell had a return on equity of 8.00% and a net margin of 8.37%.The company had revenue of $5.51 million for the quarter.</p>
<div class="lb-trans"><p>ImmuCell（納斯達克代碼：ICCC - 獲取免費報告）最近在 11 月 13 日（星期四）發佈了季度財報。這家生物技術公司報告的每股收益（EPS）為（0.02）美元。ImmuCell 的股本回報率為 8.00%，淨利潤率為 8.37%。該公司在本季度的收入為 555 萬美元。</p>
</div><h2>Hedge Funds Weigh In On ImmuCell</h2>
<div class="lb-trans"><h2>對 ImmuCell 的對沖基金觀點</h2>
</div><p>A hedge fund recently raised its stake in ImmuCell stock. Geode Capital Management LLC raised its position in shares of ImmuCell Corporation (NASDAQ:ICCC - Free Report) by 4.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 71,852 shares of the biotechnology company's stock after purchasing an additional 2,907 shares during the quarter. Geode Capital Management LLC owned 0.79% of ImmuCell worth $500,000 at the end of the most recent quarter. 13.47% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一家對沖基金最近增加了對 ImmuCell 股票的持股。根據該公司在最近向證券交易委員會提交的 13F 文件，Geode Capital Management LLC 在第二季度將其在 ImmuCell Corporation（納斯達克代碼：ICCC - 免費報告）的持股增加了 4.2%。該公司在本季度購買了額外的 2,907 股後，持有 71,852 股生物技術公司的股票。Geode Capital Management LLC 在最近一個季度末持有 ImmuCell 的 0.79%，價值 50 萬美元。13.47% 的股票由機構投資者持有。</p>
</div><h2>About ImmuCell</h2>
<div class="lb-trans"><h2>關於 ImmuCell</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>ImmuCell Corporation NASDAQ: ICCC is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.</p>
<div class="lb-trans"><p>ImmuCell Corporation（納斯達克代碼：ICCC）是一家生物技術公司，開發、製造和銷售旨在增強奶牛和肉牛健康的免疫產品和診斷試劑。公司總部位於緬因州波特蘭，專注於通過其被動免疫解決方案和獸醫診斷產品支持羣體健康管理。</p>
</div><p>The company's flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.</p>
<div class="lb-trans"><p>該公司的旗艦產品 CalfGuard 天然初乳補充劑旨在促進新生小牛抗體的被動轉移，並減少新生疾病的發生率。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than ImmuCell</li>
<li>The boring AI play that could pay up to $4,290 monthly</li>
<li>Trump’s “real estate deal for America” explained</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>Trump Did WHAT??</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 ImmuCell 更好</li>
<li>可能每月支付高達 4,290 美元的無聊 AI 投資</li>
<li>特朗普的 “美國房地產交易” 解析</li>
<li>在 1 月 1 日之前投資 1,000 美元於這隻股票 [不是 NVDA]</li>
<li>警報：在 2026 年 1 月之前拋售這五隻股票！</li>
<li>特朗普做了什麼？？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ImmuCell Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元於 ImmuCell 嗎？</h2>
</div><p>Before you consider ImmuCell, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 ImmuCell 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 ImmuCell 並不在名單上。</p>
</div><p>While ImmuCell currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 ImmuCell 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

ImmuCell（NASDAQ:ICCC）股價跌破 200 日移動平均線 - 現在是賣出的時候嗎？